NEUREN PHARMACEUTICALS LIMITED - Announcements

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

NEU	First subject commences Neuren's Rett syndrome Phase 2 trial-NEU.AX	PRICE SENSITIVE	07/04/16	104.52KB	Share
NEU	Appendix 4E and Financial Report 31 December 2015	PRICE SENSITIVE	25/02/16	628.22KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	55.25KB	Share
NEU	Trofinetide successful in Phase 2 trial in Fragile X	PRICE SENSITIVE	07/12/15	266.53KB	Share
NEU	Trading Halt	PRICE SENSITIVE	03/12/15	144.62KB	Share
NEU	Grant of composition patent in Europe for Neuren's NNZ-2591	PRICE SENSITIVE	30/11/15	99.37KB	Share
NEU	Shareholders provide further support for Rett syndrome	PRICE SENSITIVE	09/11/15	103.44KB	Share
NEU	Neuren completes enrolment in INTREPID clinical trial	PRICE SENSITIVE	29/10/15	98.93KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/15	55.15KB	Share
NEU	IRSF confirms financial support for Neuren's clinical trials	PRICE SENSITIVE	13/10/15	105.91KB	Share
NEU	New US patent covering use of trofinetide for Rett syndrome	PRICE SENSITIVE	12/10/15	102.34KB	Share
NEU	Half Yearly Report and Accounts 30 June 2015	PRICE SENSITIVE	25/08/15	2.33MB	Share
NEU	Neuren confirms orphan drug designations in Europe	PRICE SENSITIVE	13/08/15	102.28KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	54.99KB	Share
NEU	Neuren reports progress in orphan drug programs	PRICE SENSITIVE	29/07/15	119.75KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	21/04/15	54.92KB	Share
NEU	Neuren receives response to request for Breakthrough Therapy	PRICE SENSITIVE	02/03/15	106.95KB	Share
NEU	Preliminary Final Report and 2014 full year accounts	PRICE SENSITIVE	25/02/15	308.57KB	Share
NEU	FDA grants Neuren Orphan Drug designation for Rett syndrome	PRICE SENSITIVE	16/02/15	105.53KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	22/01/15	55.3KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	05/01/15	75.62KB	Share
NEU	Neuren submits Orphan Drug/Breakthrough Therapy applications	PRICE SENSITIVE	30/12/14	112.41KB	Share
NEU	Neuren successful in Rett syndrome Phase 2 trial	PRICE SENSITIVE	12/11/14	307.45KB	Share
NEU	Trading Halt	PRICE SENSITIVE	10/11/14	88.5KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	17/10/14	55.24KB	Share
NEU	Enrolment commences in Neuren's Concussion Phase 2 trial	PRICE SENSITIVE	08/09/14	104.78KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/08/14	504.07KB	Share
NEU	Neuren advances NNZ-2591 towards IND application	PRICE SENSITIVE	12/08/14	105.14KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	18/07/14	55.26KB	Share
NEU	US$3m increase to US Army grant and INTREPID outlook update	PRICE SENSITIVE	17/07/14	103.73KB	Share
NEU	Neuren receives ethics approval to start Concussion trial	PRICE SENSITIVE	10/07/14	103.23KB	Share
NEU	Neuren completes enrolment in Phase 2 trial in Rett Syndrome	PRICE SENSITIVE	26/06/14	99.27KB	Share
NEU	Neuren receives new US patent for NNZ-2591	PRICE SENSITIVE	04/06/14	94.34KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/14	55.39KB	Share
NEU	Preliminary Final Report and audited Financial Statements	PRICE SENSITIVE	27/02/14	2.45MB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	55.23KB	Share
NEU	Neuren reports progress in NNZ-2566 clinical trial programs	PRICE SENSITIVE	28/01/14	121.3KB	Share
NEU	Share Purchase Plan offer documents	PRICE SENSITIVE	30/10/13	360.05KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/13	73.31KB	Share
NEU	Orphan drug designation from FDA for NNZ-2566 in Fragile X	PRICE SENSITIVE	30/10/13	99.4KB	Share
NEU	Placement of $21.5m to accelerate execution of strategy	PRICE SENSITIVE	22/10/13	101.31KB	Share
NEU	Neuren receives Fast Track designation for Fragile X	PRICE SENSITIVE	18/10/13	97.96KB	Share
NEU	Trading Halt	PRICE SENSITIVE	18/10/13	50.9KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	09/10/13	75.1KB	Share
NEU	Neuren opens new IND for NNZ-2566 in Fragile X Syndrome	PRICE SENSITIVE	09/09/13	123.5KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	29/08/13	560.13KB	Share
NEU	Response to social media commentary re Rett trial	PRICE SENSITIVE	05/08/13	338.1KB	Share
NEU	Trading Halt	PRICE SENSITIVE	05/08/13	25.94KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/13	244.41KB	Share
NEU	Results in Fragile X Model with NNZ 2591	PRICE SENSITIVE	29/07/13	465.64KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	26/07/13	137.93KB	Share
NEU	Neuren receives two new patents	PRICE SENSITIVE	12/07/13	339.63KB	Share
NEU	Response to ASX Price Query Letter	PRICE SENSITIVE	25/06/13	136.75KB	Share
NEU	FDA Fast Track granted for NNZ2566 Rett program	PRICE SENSITIVE	05/06/13	347.82KB	Share
NEU	Response to ASX Price Query Letter	PRICE SENSITIVE	15/05/13	136.73KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/13	244.1KB	Share
NEU	Shareholder Update	PRICE SENSITIVE	15/04/13	1.05MB	Share
NEU	Preliminary Final Report	PRICE SENSITIVE	28/02/13	336.84KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	232.42KB	Share
NEU	Neuren IND open for Rett Phase II trial	PRICE SENSITIVE	24/12/12	242.83KB	Share
NEU	Neuren TAP Conference presentation and Fragile X results	PRICE SENSITIVE	30/11/12	1.22MB	Share
NEU	Neuren completes Phase I NNZ2566 study/files Phase II IND	PRICE SENSITIVE	22/11/12	182.8KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	243.67KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	25/10/12	146KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/12	805.05KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	232.44KB	Share
NEU	Neuren awarded Rett Syndrome trial grant	PRICE SENSITIVE	06/07/12	220.81KB	Share
NEU	Neuren announces cancer xenograft testing results	PRICE SENSITIVE	29/05/12	142.69KB	Share
NEU	Rett Syndrome pre-IND meeting held with FDA	PRICE SENSITIVE	16/05/12	47.48KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	121.12KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	19/04/12	118.49KB	Share
NEU	Neuren 2011 Preliminary Final Report	PRICE SENSITIVE	29/02/12	63.32KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	143.59KB	Share
NEU	Neuren to proceed with oral NNZ2566 trial	PRICE SENSITIVE	22/12/11	40.08KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	09/12/11	145.65KB	Share
NEU	Neuren Completes Phase II trial Cohort 2	PRICE SENSITIVE	21/11/11	43.94KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/11	144.26KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	20/10/11	165.42KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/11	698.85KB	Share
AEF +NEU	Neuren places $3m of rights issue shortfall	PRICE SENSITIVE	16/08/11	39.13KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/11	91.69KB	Share
NEU	Neuren Rights Issue Letter of Offer (Australian residents)	PRICE SENSITIVE	15/06/11	765.09KB	Share
NEU	Neuren Rights Issue Offer Document (NZ residents)	PRICE SENSITIVE	15/06/11	793.18KB	Share
NEU	Neuren announces Renounceable Rights Issue	PRICE SENSITIVE	15/06/11	22.64KB	Share
NEU	Neuren reduces outstanding convertible note principal	PRICE SENSITIVE	20/05/11	23.25KB	Share
NEU	Neuren's Perseis selects lead antibodies	PRICE SENSITIVE	19/05/11	713.58KB	Share
NEU	Neuren Completes Phase II trial Cohort 1	PRICE SENSITIVE	11/05/11	26.32KB	Share
NEU	Neuren Announces Private Placement and Rights Issue	PRICE SENSITIVE	04/05/11	25.82KB	Share
NEU	Trading Halt	PRICE SENSITIVE	02/05/11	95.34KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/11	93.43KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	10/03/11	133.86KB	Share
NEU	Preliminary Final Report	PRICE SENSITIVE	28/02/11	67.49KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/11	82.43KB	Share
NEU	Neuren Initiates NNZ2566 Oral Formulation Development	PRICE SENSITIVE	18/11/10	44.72KB	Share
NEU	Neuren Completes Additional Phase I Study for TBI	PRICE SENSITIVE	16/11/10	50.33KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/10	109.83KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	26/08/10	395.4KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	28/07/10	113.33KB	Share
NEU	Neuren Starts Phase II Trial of NNZ2566	PRICE SENSITIVE	06/05/10	39.74KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/10	101.43KB	Share

NEU First subject commences Neuren's Rett syndrome Phase 2 trial-NEU.AX
07/04/16	PRICE SENSITIVE	104.52KB	Share
NEU Appendix 4E and Financial Report 31 December 2015
25/02/16	PRICE SENSITIVE	628.22KB	Share
NEU Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	55.25KB	Share
NEU Trofinetide successful in Phase 2 trial in Fragile X
07/12/15	PRICE SENSITIVE	266.53KB	Share
NEU Trading Halt
03/12/15	PRICE SENSITIVE	144.62KB	Share
NEU Grant of composition patent in Europe for Neuren's NNZ-2591
30/11/15	PRICE SENSITIVE	99.37KB	Share
NEU Shareholders provide further support for Rett syndrome
09/11/15	PRICE SENSITIVE	103.44KB	Share
NEU Neuren completes enrolment in INTREPID clinical trial
29/10/15	PRICE SENSITIVE	98.93KB	Share
NEU Appendix 4C - quarterly
21/10/15	PRICE SENSITIVE	55.15KB	Share
NEU IRSF confirms financial support for Neuren's clinical trials
13/10/15	PRICE SENSITIVE	105.91KB	Share
NEU New US patent covering use of trofinetide for Rett syndrome
12/10/15	PRICE SENSITIVE	102.34KB	Share
NEU Half Yearly Report and Accounts 30 June 2015
25/08/15	PRICE SENSITIVE	2.33MB	Share
NEU Neuren confirms orphan drug designations in Europe
13/08/15	PRICE SENSITIVE	102.28KB	Share
NEU Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	54.99KB	Share
NEU Neuren reports progress in orphan drug programs
29/07/15	PRICE SENSITIVE	119.75KB	Share
NEU Appendix 4C - quarterly
21/04/15	PRICE SENSITIVE	54.92KB	Share
NEU Neuren receives response to request for Breakthrough Therapy
02/03/15	PRICE SENSITIVE	106.95KB	Share
NEU Preliminary Final Report and 2014 full year accounts
25/02/15	PRICE SENSITIVE	308.57KB	Share
NEU FDA grants Neuren Orphan Drug designation for Rett syndrome
16/02/15	PRICE SENSITIVE	105.53KB	Share
NEU Appendix 4C - quarterly
22/01/15	PRICE SENSITIVE	55.3KB	Share
NEU Response to ASX Price Query
05/01/15	PRICE SENSITIVE	75.62KB	Share
NEU Neuren submits Orphan Drug/Breakthrough Therapy applications
30/12/14	PRICE SENSITIVE	112.41KB	Share
NEU Neuren successful in Rett syndrome Phase 2 trial
12/11/14	PRICE SENSITIVE	307.45KB	Share
NEU Trading Halt
10/11/14	PRICE SENSITIVE	88.5KB	Share
NEU Appendix 4C - quarterly
17/10/14	PRICE SENSITIVE	55.24KB	Share
NEU Enrolment commences in Neuren's Concussion Phase 2 trial
08/09/14	PRICE SENSITIVE	104.78KB	Share
NEU Half Yearly Report and Accounts
28/08/14	PRICE SENSITIVE	504.07KB	Share
NEU Neuren advances NNZ-2591 towards IND application
12/08/14	PRICE SENSITIVE	105.14KB	Share
NEU Appendix 4C - quarterly
18/07/14	PRICE SENSITIVE	55.26KB	Share
NEU US$3m increase to US Army grant and INTREPID outlook update
17/07/14	PRICE SENSITIVE	103.73KB	Share
NEU Neuren receives ethics approval to start Concussion trial
10/07/14	PRICE SENSITIVE	103.23KB	Share
NEU Neuren completes enrolment in Phase 2 trial in Rett Syndrome
26/06/14	PRICE SENSITIVE	99.27KB	Share
NEUNeuren receives new US patent for NNZ-2591
04/06/14	PRICE SENSITIVE	94.34KB	Share
NEUAppendix 4C - quarterly
30/04/14	PRICE SENSITIVE	55.39KB	Share
NEUPreliminary Final Report and audited Financial Statements
27/02/14	PRICE SENSITIVE	2.45MB	Share
NEUAppendix 4C - quarterly
31/01/14	PRICE SENSITIVE	55.23KB	Share
NEUNeuren reports progress in NNZ-2566 clinical trial programs
28/01/14	PRICE SENSITIVE	121.3KB	Share
NEUShare Purchase Plan offer documents
30/10/13	PRICE SENSITIVE	360.05KB	Share
NEUAppendix 4C - quarterly
30/10/13	PRICE SENSITIVE	73.31KB	Share
NEUOrphan drug designation from FDA for NNZ-2566 in Fragile X
30/10/13	PRICE SENSITIVE	99.4KB	Share
NEUPlacement of $21.5m to accelerate execution of strategy
22/10/13	PRICE SENSITIVE	101.31KB	Share
NEUNeuren receives Fast Track designation for Fragile X
18/10/13	PRICE SENSITIVE	97.96KB	Share
NEUTrading Halt
18/10/13	PRICE SENSITIVE	50.9KB	Share
NEUResponse to ASX Price Query
09/10/13	PRICE SENSITIVE	75.1KB	Share
NEUNeuren opens new IND for NNZ-2566 in Fragile X Syndrome
09/09/13	PRICE SENSITIVE	123.5KB	Share
NEUHalf Yearly Report and Accounts
29/08/13	PRICE SENSITIVE	560.13KB	Share
NEUResponse to social media commentary re Rett trial
05/08/13	PRICE SENSITIVE	338.1KB	Share
NEUTrading Halt
05/08/13	PRICE SENSITIVE	25.94KB	Share
NEUAppendix 4C - quarterly
31/07/13	PRICE SENSITIVE	244.41KB	Share
NEUResults in Fragile X Model with NNZ 2591
29/07/13	PRICE SENSITIVE	465.64KB	Share
NEUResponse to ASX Price Query
26/07/13	PRICE SENSITIVE	137.93KB	Share
NEUNeuren receives two new patents
12/07/13	PRICE SENSITIVE	339.63KB	Share
NEUResponse to ASX Price Query Letter
25/06/13	PRICE SENSITIVE	136.75KB	Share
NEUFDA Fast Track granted for NNZ2566 Rett program
05/06/13	PRICE SENSITIVE	347.82KB	Share
NEUResponse to ASX Price Query Letter
15/05/13	PRICE SENSITIVE	136.73KB	Share
NEUAppendix 4C - quarterly
30/04/13	PRICE SENSITIVE	244.1KB	Share
NEUShareholder Update
15/04/13	PRICE SENSITIVE	1.05MB	Share
NEUPreliminary Final Report
28/02/13	PRICE SENSITIVE	336.84KB	Share
NEUAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	232.42KB	Share
NEUNeuren IND open for Rett Phase II trial
24/12/12	PRICE SENSITIVE	242.83KB	Share
NEUNeuren TAP Conference presentation and Fragile X results
30/11/12	PRICE SENSITIVE	1.22MB	Share
NEUNeuren completes Phase I NNZ2566 study/files Phase II IND
22/11/12	PRICE SENSITIVE	182.8KB	Share
NEUAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	243.67KB	Share
NEUResponse to ASX Price Query
25/10/12	PRICE SENSITIVE	146KB	Share
NEUHalf Yearly Report and Accounts
30/08/12	PRICE SENSITIVE	805.05KB	Share
NEUAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	232.44KB	Share
NEUNeuren awarded Rett Syndrome trial grant
06/07/12	PRICE SENSITIVE	220.81KB	Share
NEUNeuren announces cancer xenograft testing results
29/05/12	PRICE SENSITIVE	142.69KB	Share
NEURett Syndrome pre-IND meeting held with FDA
16/05/12	PRICE SENSITIVE	47.48KB	Share
NEUAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	121.12KB	Share
NEUResponse to ASX Price Query
19/04/12	PRICE SENSITIVE	118.49KB	Share
NEUNeuren 2011 Preliminary Final Report
29/02/12	PRICE SENSITIVE	63.32KB	Share
NEUAppendix 4C - quarterly
31/01/12	PRICE SENSITIVE	143.59KB	Share
NEUNeuren to proceed with oral NNZ2566 trial
22/12/11	PRICE SENSITIVE	40.08KB	Share
NEUResponse to ASX Price Query
09/12/11	PRICE SENSITIVE	145.65KB	Share
NEUNeuren Completes Phase II trial Cohort 2
21/11/11	PRICE SENSITIVE	43.94KB	Share
NEUAppendix 4C - quarterly
28/10/11	PRICE SENSITIVE	144.26KB	Share
NEUResponse to ASX Price Query
20/10/11	PRICE SENSITIVE	165.42KB	Share
NEUHalf Yearly Report and Accounts
30/08/11	PRICE SENSITIVE	698.85KB	Share
AEF +NEUNeuren places $3m of rights issue shortfall
16/08/11	PRICE SENSITIVE	39.13KB	Share
NEUAppendix 4C - quarterly
29/07/11	PRICE SENSITIVE	91.69KB	Share
NEUNeuren Rights Issue Letter of Offer (Australian residents)
15/06/11	PRICE SENSITIVE	765.09KB	Share
NEUNeuren Rights Issue Offer Document (NZ residents)
15/06/11	PRICE SENSITIVE	793.18KB	Share
NEUNeuren announces Renounceable Rights Issue
15/06/11	PRICE SENSITIVE	22.64KB	Share
NEUNeuren reduces outstanding convertible note principal
20/05/11	PRICE SENSITIVE	23.25KB	Share
NEUNeuren's Perseis selects lead antibodies
19/05/11	PRICE SENSITIVE	713.58KB	Share
NEUNeuren Completes Phase II trial Cohort 1
11/05/11	PRICE SENSITIVE	26.32KB	Share
NEUNeuren Announces Private Placement and Rights Issue
04/05/11	PRICE SENSITIVE	25.82KB	Share
NEUTrading Halt
02/05/11	PRICE SENSITIVE	95.34KB	Share
NEUAppendix 4C - quarterly
29/04/11	PRICE SENSITIVE	93.43KB	Share
NEUResponse to ASX Price Query
10/03/11	PRICE SENSITIVE	133.86KB	Share
NEUPreliminary Final Report
28/02/11	PRICE SENSITIVE	67.49KB	Share
NEUAppendix 4C - quarterly
31/01/11	PRICE SENSITIVE	82.43KB	Share
NEUNeuren Initiates NNZ2566 Oral Formulation Development
18/11/10	PRICE SENSITIVE	44.72KB	Share
NEUNeuren Completes Additional Phase I Study for TBI
16/11/10	PRICE SENSITIVE	50.33KB	Share
NEUAppendix 4C - quarterly
27/10/10	PRICE SENSITIVE	109.83KB	Share
NEUHalf Yearly Report and Accounts
26/08/10	PRICE SENSITIVE	395.4KB	Share
NEUAppendix 4C - quarterly
28/07/10	PRICE SENSITIVE	113.33KB	Share
NEUNeuren Starts Phase II Trial of NNZ2566
06/05/10	PRICE SENSITIVE	39.74KB	Share
NEUAppendix 4C - quarterly
30/04/10	PRICE SENSITIVE	101.43KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	667	13.080
2	154	13.000
1	77	12.930
1	39	12.920
1	21	12.900

Price($)	Vol.	No.
13.190	1305	1
13.560	2250	1
13.880	748	1
14.000	60	1
14.020	10000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories